MBX Biosciences
Carmel, US · Founded 2019 · 93 employees on LinkedIn · 5 known investors
Find your way into MBX Biosciences
573 people in our graph share verified history with the MBX Biosciences team — schools, employers, funds. One of them is your warm intro.
Giuseppe Donvitounlockedknows Mark Soued · together at Northwestern University - Kellogg School of Management (overlapped)
knows the team · via Alnylam
×2knows the team · via Northwestern University - Kellogg School of Management
×3knows the team · via Amgen
×3knows the team · via University of Colorado
×2knows the team · via Sienna Biopharmaceuticals
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.
Founders & leadership
MBX Biosciences was founded in 2019 by Richard DiMarchi and Peter Kent Hawryluk.
RD
Richard DiMarchiCo-founder
PK
Peter Kent HawrylukCo-founder
TK
Timothy KnickerbockerinChief Operating Officer2018–2022
SH
Steve HoerterinChairman & Chief Executive Officer
SA
Salomon AzoulayinChief Medical Officer
KB
Karen BasbauminChief Business Officer
MG
Michelle GrahaminChief Human Resources OfficerMichelle Graham is Chief Human Resources Officer at MBX Biosciences, a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. She has held HR leadership roles across biotechnology, biopharmaceutical services, medical devices, and consumer products companies, ranging from startups to Fortune 500 organizations.
JS
MS
Mark SouedinChief Commercial OfficerChief Commercial Officer of MBX Biosciences, a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. Soued has held commercial leadership roles across multiple therapeutic areas and geographies in the biopharmaceutical industry.
Investors · 5
Reported raises · per SEC filings
Form D private placements$74.8M disclosed across 3 rounds · 2019–2022
▶$46.7MraisedNov 2022 · 20 investors · PharmaceuticalsRule 506(b)
▶$46.7MraisedNov 2022 · 20 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- James M. CorneliusDirector
- Patrick HeronDirector
- Edward MathersDirector
- Richard DiMarchiExecutive Officer, Director
- Tiba AynechiDirector
- Peter Kent HawrylukExecutive Officer, Director
- Ora PescovitzDirector
- Carl GordonDirector
- Richard BartramExecutive Officer
- Offering amount
- $115.2M
- Amount sold
- $46.7M
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$25.8MraisedJul 2020 · 16 investors · PharmaceuticalsRule 506(b)
▶$25.8MraisedJul 2020 · 16 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Timothy KnickerbockerExecutive Officer, Director
- Richard DiMarchiExecutive Officer, Director
- Peter Kent HawrylukExecutive Officer, Director
- Offering amount
- $35.8M
- Amount sold
- $25.8M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$2.3MraisedMay 2019 · 9 investors · PharmaceuticalsRule 506(b)
▶$2.3MraisedMay 2019 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Richard DiMarchiExecutive Officer, Director
- Timothy KnickerbockerExecutive Officer, Director
- Peter Kent HawrylukExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $2.3M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does MBX Biosciences do?
- MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.
- Who founded MBX Biosciences?
- MBX Biosciences was founded by Richard DiMarchi, Peter Kent Hawryluk in 2019.
- Who are MBX Biosciences's investors?
- MBX Biosciences's investors include Frazier Life Sciences, Norwest Venture Partners, IU Ventures, New Enterprise Associates (NEA), OrbiMed.
- How much funding has MBX Biosciences raised?
- MBX Biosciences has disclosed $74.8M raised across 3 rounds.
- Where is MBX Biosciences headquartered?
- MBX Biosciences is headquartered in Carmel, US.